Crescent Biopharma, Inc.
CBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001253689
In the last 90 days, Crescent Biopharma, Inc. insiders filed 0 open-market purchases and 7 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $532.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $558.9M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $285.5K in total
- 7
- 13F holdersQ2 2026, +19 vs. previous quarter
- 82
- 13F valueReported value at the end of Q2 2026
- $532.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $10.8M
- No comparable prior period
- Net income, FY2025
- -$153.9M
- No comparable prior period
- Free cash flow, FY2025
- -$72.5M
- No comparable prior period
- Revenue, Q3 FY2026
- $3.12M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $153.9M (1419.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.16M
- Shares sold short
- Change
- −258.4K
- −5.9% vs. previous
- Days to cover
- 16.29
- At average daily volume
Superinvestors holding CBIO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CBIO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Crescent Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:03 PM ET | Sep 16 | 2 days | Lynch RyanSee Remarks | SSale | −240 | $17.90 | −$4.30K | −1.7%13.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:03 PM ET | Sep 16 | 2 days | Pinkas JanChief Scientific Officer | SSale | −658 | $17.90 | −$11.8K | −3.0%21.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Im Ellie EunkyungChief Medical Officer | SSale | −623 | $17.90 | −$11.2K | −2.8%21.4K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Scalzo Richard WilliamChief Financial Officer | SSale | −568 | $17.90 | −$10.2K | −2.8%19.7K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Bispham Barbara HarlinSee Remarks | SSale | −620 | $17.90 | −$11.1K | −3.2%18.7K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16-18 | 2 days | Brumm Joshua TChief Executive Officer | SSale | −9.45K | $16.91 | −$159.8K | −3.4%271.8K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)4:01 PM ET | Sep 16-18 | 2 days | McNeill JonathanPresident and COO | SSale | −4.57K | $16.90 | −$77.2K | −3.3%134.6K after | 2 lots10b5-1 |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +853.5K | $14.50 | +$12.4M | +31.1%3.60M after | |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +525.9K | $14.50 | +$7.62M | –2.29M after | Derivative |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Lynch RyanSee Remarks | SSale | −465 | $17.99 | −$8.37K | −3.2%13.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 82 holdersThe largest institutional positions in Crescent Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,133,514 | $74.4M | 0.00% | 00.0% | Unchanged |
| BVF Inc | 2,748,763 | $49.5M | 1.27% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 2,747,866 | $49.5M | 3.27% | 00.0% | Unchanged |
| VR Adviser, LLC | 2,133,576 | $38.4M | 1.16% | 00.0% | Unchanged |
| Logos Global Management LP | 1,900,000 | $34.2M | 1.47% | +1,417,500+293.8% | Added |
| FCPM III Services B.V. | 1,677,852 | $30.2M | 4.02% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 1,662,917 | $29.9M | 0.05% | +152,884+10.1% | Added |
| Vestal Point Capital, LP | 1,630,000 | $29.3M | 0.69% | +130,000+8.7% | Added |
| Opaleye Management Inc. | 1,319,351 | $23.7M | 2.15% | +6,736+0.5% | Added |
| BlackRock, Inc. | 1,271,762 | $22.9M | 0.00% | +1,156,037+999.0% | Added |
Holders of 5% or more of CBIO
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Crescent Biopharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D/A | 16.52%6.60M shares | −2.01 ppfrom 18.53% | Jun 23, 20253 filings | Jul 20, 2026 | SEC |
| FMR LLC | 13G/A | 15.00%4.13M shares | +4.80 ppfrom 10.20% | Jul 8, 20252 filings | Feb 5, 2026 | SEC |
| 1Globe Capital LLC | 13G/A | 10.30%1.43M shares | +3.85 ppfrom 6.45% | Aug 20, 20252 filings | Oct 14, 2025 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.99%1.39M shares | – | Feb 11, 20213 filings | Aug 14, 2025 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.50%2.67M shares | −0.40 ppfrom 9.90% | Jun 23, 20252 filings | Feb 17, 2026 | SEC |